Revealed: Prices of some leading COVID-19 vaccine candidates

World

Login / Sign Up

Friday, September 18, 2020

Gold / Forex

World

Revealed: Prices of some leading COVID-19 vaccine candidates

Vaccine makers reveal prices of their jabs undergoing final human trials

Published: August 23, 2020 18:03 Jay Hilotin, Senior Assistant Editor

1 of 10

Gulf News — LEADING THE RACE: There are at least six leading vaccine candidates from around the world currently in late-stage (Phase 3) trials. Altogether, an estimated 150 coronavirus vaccines are in development. A heightened sense of altruism by tens of thousands of volunteers, plus the ease of enlisting and monitoring them through cloud-based portals are key factors driving vaccine developments. These greatly help speed up the trial process, compared to previous pandemics. Hopes are high that at least one vaccine would hit the market in record time to ease its crippling economic effects. Image Credit: File / Gulf News

2 of 10

Modern MRNA mRNA-1273 — MESSENGER RNA: The Massachusetts-based biotech company is working in collaboration with the US National Institutes of Health. This new type of vaccine relies on injecting components of a virus’s genetic material, a messenger RNA (mRNA), into human cells. Unlike other vaccines, it doesn't use an actual virus. Instead, it creates viral proteins that mimic the coronavirus. As such it trains the human immune system to get activated. The technology is platform, yet unproven. If it succeeds, however, mRNA-1273 would be the first such vaccine approved for human use. How mRNA vaccine works: https://gn24.ae/9f1d22dc3395000 Image Credit: AFP

3 of 10

Pfizer vaccine BNT162b2 — SUPPLY CONTRACT SIGNED: New York-based Pfizer is working with German biotech company BioNTech. Their vaccine project is also based on the mRNA platform from the German company’s earlier efforts on experimental cancer vaccines. Pfizer has signed a $1.95 billion supply contract with the US government to provide 100 million doses by December 2020. The deal kicks in when and if the drug is approved. On July 27, 2020, they started the BNT162b2 trial which combines Phases 2 and 3 by enrolling 30,000 people from 39 US states and from Brazil, Argentina, and Germany. They are aiming to seek regulatory approval by October 2020. Image Credit: Reuters

4 of 10

Oxford vaccine — SHOT FROM OXFORD OUT IN SEPTEMBER?: Also known as the ChAdOx1 nCoV-19, the vaccine was developed by researchers at the University of Oxford. They begun enrolling subjects in a phase 2/3 clinical trial of AstraZeneca-partnered COVID-19 vaccine AZD1222. The project completed a 1,000-subject phase 1, and now working on a 10,260-subject Phase 3 in the UK. If successful, the first shipments to customers could be out in September. Image Credit: Supplied

5 of 10

Sinopharm's New Crown — $145 FOR TWO SHOTS*: Sinopharm's China National Biotec Group (CNBG), a state-owned pharmaceutical company, says that its COVID-19 vaccine will reach market by December. “It is expected to cost a few hundred yuan for a shot, and for two shots it should be less than 1000 yuan ($145),” Sinopharm CEO Liu Jingzhen, told Guangming Daily newspaper last week. On July 26, 2020, the Phase 3 trial for the SinoPharm vaccine kicked off in Abu Dhabi, UAE, which quickly signed up 15,000 volunteers. It was the world's first Phase 3 clinical trial of the COVID-19 "inactivated" vaccine. Image Credit: CNBG

6 of 10

Sinovac Biotech's CoronaVac — INACTIVATED VACCINE: Sinovac Biotech's CoronaVac SARS-CoV-2 Vaccine candidate is based on an inactivated pathogen. A phase 3 clinical trial aims to recruit 9,000 people, mostly healthcare professionals, working in COVID-19 specialised facilities in 12 clinical sites, located in several states in Brazil. No price was given by the developers yet. Image Credit: Xinhua

7 of 10

Cansino Ad5-nCoV vaccine — APPROVED FOR USE IN THE CHINESE MILITARY: The Ad5-nCoV vaccine candidate is a genetically engineered vaccine candidate with the adenovirus type 5 as the "vector" (carrier) to express SARS-CoV-2 spike protein. The vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform. The vaccine was co-developed by the Beijing Institute of Biotechnology. On June 29, 2020, China's Central Military Commission gave its approval for Ad5-nCoV to be used in the Chinese military from one year. Image Credit: File

8 of 10

Serum Institute — READY FOR MASS PRODUCTION: Serum Institute, an Indian biotech firm and the world's largest vaccine maker by volume, is girding up for hundreds of millions of shots. It invisages a price of Rs1,000 ($13.20) per show, though governments may give it to their people without charge, said Serum Institute's Cyrus Poonawalla. According to Suresh Jadhav, Executive Director of SII, the company will start manufacturing the vaccine the moment the Phase-3 trial (vaccine given to thousands of people) or the combined Phase-2/Phase-3 trial begins. Image Credit: Oxford

9 of 10

Sputnik V Gamaleya — PARTNERSHIP WITH INDIA: On August 11, 2020. Russian President Vladimir Putin said Russia’s Sputnik V was the “world's first vaccine against COVID-19”, which works "quite effectively" and forms a "stable immunity" against the disease. It was developed by Gamaleya Research Institute of Epidemiology and Microbiology. Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF), who developed the shot with Gamaleya, said they are looking for a partnership with India to mass produce the jab. He said several nations in Latin America, Asia and the Middle East are also interested in mass producing it. The vaccine is slated for Phase 3 or larger clinical trials. No price was given yet for the Russian vaccine. Image Credit: AFP

10 of 10

Gavi vaccine price drop — PRICE DROP: Prices of vaccines eventually drop over time. There's also a growing evidence that the GAVI Vaccine Alliance is helping bring down prices for vaccines. This happened for hepatitis B, DTP-hepB and one-in-five pentavalent vaccines. Graph shows Price decline of hepatitis B vaccines. Under a new landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation announced on August 7, 2020, manufacturing and delivery of up to 100 million doses of future safe and effective COVID-19 vaccines will be accelerated for low- and middle-income countries in 2021. Image Credit: Gavi / NICEF Supply Division, 2010

Latest In

Imran Khan’s aide summoned over abduction of officer

3 minutes ago
Iraqi siblings script bone marrow success in India

23 minutes ago
IPL: CSK prepare for a perfect launch

37 minutes ago
UAE: 10 natural hidden gems in the country

44 minutes ago
COVID-19: Bahrain delays nursery reopening

52 minutes ago

This website stores cookies on your computer. These cookies are used to improve your experience and provide more personalized service to you. Both on your website and other media. To find out more about the cookies and data we use, please check out our Privacy Policy.